118 related articles for article (PubMed ID: 11074907)
1. Methylene blue and cirrhosis: pathophysiologic insights, therapeutic dilemmas.
Fallon MB
Ann Intern Med; 2000 Nov; 133(9):738-40. PubMed ID: 11074907
[No Abstract] [Full Text] [Related]
2. Methylene blue improves the hepatopulmonary syndrome.
Schenk P; Madl C; Rezaie-Majd S; Lehr S; Müller C
Ann Intern Med; 2000 Nov; 133(9):701-6. PubMed ID: 11074903
[TBL] [Abstract][Full Text] [Related]
3. Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome.
Jounieaux V; Leleu O; Mayeux I
Intensive Care Med; 2001 Jun; 27(6):1103-4. PubMed ID: 11497151
[No Abstract] [Full Text] [Related]
4. Methylene blue improves the hepatopulmonary syndrome.
Groneberg DA; Fischer A
Ann Intern Med; 2001 Sep; 135(5):380-1. PubMed ID: 11529704
[No Abstract] [Full Text] [Related]
5. [Hepatopulmonary syndrome].
Thevenot T; Pastor CM; Cervoni JP; Jacquelinet C; Nguyen-Khac E; Richou C; Heyd B; Vanlemmens C; Mantion G; Di Martino V; Cadranel J
Gastroenterol Clin Biol; 2009; 33(6-7):565-79. PubMed ID: 19481392
[TBL] [Abstract][Full Text] [Related]
6. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome.
Almeida JA; Riordan SM; Liu J; Galhenage S; Kim R; Bihari D; Wegner EA; Cranney GB; Thomas PS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):341-6. PubMed ID: 17353701
[TBL] [Abstract][Full Text] [Related]
7. Methylene blue as drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass.
Evora PR; Levin RL
J Thorac Cardiovasc Surg; 2004 Mar; 127(3):895-6; author reply 896. PubMed ID: 15001923
[No Abstract] [Full Text] [Related]
8. Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. A medical hypothesis.
Farina Junior JA; Celotto AC; da Silva MF; Evora PR
Med Sci Monit; 2012 May; 18(5):HY13-7. PubMed ID: 22534716
[TBL] [Abstract][Full Text] [Related]
9. Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery.
Lenglet S; Mach F; Montecucco F
Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1519-25. PubMed ID: 22103871
[TBL] [Abstract][Full Text] [Related]
10. Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report.
Roma J; Balbi E; Pacheco-Moreira L; Gonzalez AC; Leal CG; Pousa F; Zynger I; Leite D; Halpern M; Guerra PP; Covelo M; Carius L; Agoglia L; Oliveira A; Enne M
Transplant Proc; 2010 Mar; 42(2):601-4. PubMed ID: 20304203
[TBL] [Abstract][Full Text] [Related]
11. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis.
Grayling M; Deakin CD
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):426-7. PubMed ID: 12579121
[No Abstract] [Full Text] [Related]
12. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?
Leyh RG; Kofidis T; Strüber M; Fischer S; Knobloch K; Wachsmann B; Hagl C; Simon AR; Haverich A
J Thorac Cardiovasc Surg; 2003 Jun; 125(6):1426-31. PubMed ID: 12830064
[TBL] [Abstract][Full Text] [Related]
13. The soluble guanylate cyclase inhibitor methylene blue evokes preterm delivery and fetal growth restriction in a mouse model.
Tiboni GM; Giampietro F; Lamonaca D
In Vivo; 2001; 15(4):333-7. PubMed ID: 11695226
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment for hepatopulmonary syndrome.
Eshraghian A; Kamyab AA; Yoon SK
Biomed Res Int; 2013; 2013():670139. PubMed ID: 24102057
[TBL] [Abstract][Full Text] [Related]
15. Methylene blue "avatar" brain.
Lummus S; Kleinschmidt-Demasters BK
J Neuropathol Exp Neurol; 2013 Mar; 72(3):263-5. PubMed ID: 23422732
[No Abstract] [Full Text] [Related]
16. Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea.
Hwang TL; Wu CC; Teng CM
Br J Pharmacol; 1998 Nov; 125(6):1158-63. PubMed ID: 9863642
[TBL] [Abstract][Full Text] [Related]
17. Methylene blue for refractory hypotension: a case report.
Weissgerber AJ
AANA J; 2008 Aug; 76(4):271-4. PubMed ID: 18777811
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity.
Fernandes D; da Silva-Santos JE; Duma D; Villela CG; Barja-Fidalgo C; Assreuy J
Mol Pharmacol; 2006 Mar; 69(3):983-90. PubMed ID: 16326931
[TBL] [Abstract][Full Text] [Related]
19. Methylene blue adjuvant therapy of schizophrenia.
Deutsch SI; Rosse RB; Schwartz BL; Fay-McCarthy M; Rosenberg PB; Fearing K
Clin Neuropharmacol; 1997 Aug; 20(4):357-63. PubMed ID: 9260734
[TBL] [Abstract][Full Text] [Related]
20. The guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target.
Evora PR; Viaro F
Curr Drug Targets; 2006 Sep; 7(9):1195-204. PubMed ID: 17017895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
